Serious adverse events
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with TURBT alone (very low certainty).
1 finding from 1 review
Serious adverse events
It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with postoperative BCG induction therapy (very low certainty).
1 finding from 1 review
Serious adverse events
It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with MMC‐PD induction therapy (very low certainty).
1 finding from 1 review
Serious adverse events · adults with episodic tension‐type headache
1 finding from 1 review
Serious adverse events · adults with fibromyalgia
1 finding from 1 review
Intervention not reported
Serious adverse events · people at risk for development of T2DM
1 finding from 1 review
Intervention not reported
Serious adverse events · people at risk for development of T2DM
1 finding from 1 review
Serious adverse events · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Serious adverse events · children (4 to 18 years) with functional abdominal pain disorders
1 finding from 1 review
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Intervention not reported
Serious adverse events · people with cancer pain
1 finding from 1 review
Intervention not reported
Serious adverse events · people with cancer pain
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Azathioprine showed no clear difference in serious adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to lower serious adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in serious Adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with GIOP
Bisphosphonates showed no clear difference in serious adverse events compared with control (low certainty).
1 finding from 1 review
Serious adverse events · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Non‐absorbable disaccharides probably leads to lower serious adverse events compared with placebo/no intervention (moderate certainty).
1 finding from 1 review